UNSPSC 51285006: Ampicillin/sulbactam

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM113. This VA Drug Class (AM113) classifies this compound as belonging to the group EXTENDED SPECTRUM PENICILLINS.

UNSPSC 51285006 Ampicillin/sulbactam is a Commodity code that nominally identifies a single antibiotic product, but recent state and local solicitations tagged under this code show little alignment with the code's pharmaceutical specificity. Instead, the opportunities posted under 51285006 span a much broader range of health and medical supplies — from naloxone and drug deactivation systems to generic multi-source pharmaceuticals, OTC products, medical and first aid supplies for emergency response, and direct-to-manufacturer prescription programs. State and local health departments, fire departments, and health-focused purchasing consortia are the primary issuing bodies. This breadth suggests either tagging inconsistency in the source data or that the code's practical use extends well beyond ampicillin/sulbactam itself to encompass pharmaceutical procurement at the commodity level more broadly.

Recent activity spans multiple states and purchasing mechanisms. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendor pricing submissions through authorized wholesalers and compliance with cGMP and Drug Supply Chain Security Act (DSCSA) standards. The City of Tampa issued an IFB for medical and first aid supplies for the Tampa Fire Department Rescue Division (169 line items, estimated contract value $700,000, due March 13, 2026) with a Small Local Business Enterprise set-aside and 5 percent bid discount. Seminole County, Florida posted an IFB for naloxone and drug deactivation systems (1,900 units naloxone and 800 deactivation systems annually, due July 26, 2023) with quarterly deliveries and potential FEMA funding. The Texas Health and Human Services Commission issued an RFI in April 2026 regarding direct-to-manufacturer prescription programs, signaling early-stage vendor outreach for future formal solicitations. The code shows activity in Florida and Minnesota, with Texas market intelligence gathering, though the diversity of products and the disconnect between code name and actual procurement scope suggest limited decision value for targeting ampicillin/sulbactam specifically.